Metagenomi Therapeutics, Inc.: updates and filings

MGXNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$0.63

November 19, 2026Market cap $24M

What Ploutos Investor adds for Metagenomi Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 83 daysAround Feb 10, 2027 · for Q4 2026

last Nov 10, 2026next Feb 10, 2027

A rough estimate from when it has reported before, which has varied. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 5, 2026 latest annualNov 10, 2026 latest quarterly
  • Nov 16, 2026Regulation FD disclosure
    Form8-K
  • Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 10, 2026Results of operations
    Form8-K
  • Sep 22, 2026Regulation FD disclosure
    Form8-K
  • Sep 10, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 10, 2026Results of operations
    Form8-K
  • Jun 10, 2026Officer or director change, shareholder vote
    Form8-K
  • May 11, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 11, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Apr 27, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 27, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 27, 2026Annual meeting proxy statement
    FormDEF 14A
  • Mar 5, 2026Shares registered for employees
    FormS-8
  • Mar 5, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 5, 2026Results of operations
    Form8-K
  • Jan 12, 2026Amended articles or bylaws, Regulation FD disclosure
    Form8-K
  • Nov 12, 2025Quarterly reportfor the period to Sep 30, 2025
    Form10-Q
  • Nov 12, 2025Results of operations, Regulation FD disclosure
    Form8-K
  • Oct 1, 2025Material agreement entered, material agreement ended
    Form8-K
  • Aug 12, 2025Quarterly reportfor the period to Jun 30, 2025
    Form10-Q
  • Aug 12, 2025Results of operations, Regulation FD disclosure
    Form8-K
  • Jun 11, 2025Shareholder vote
    Form8-K
  • May 14, 2025Other material events
    Form8-K
  • May 13, 2025Quarterly reportfor the period to Mar 31, 2025
    Form10-Q

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 16, 2019.

The full analysis

What do Metagenomi Therapeutics's filings show?

The filings are where every one of Metagenomi Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.